Merck
Sentiment Over Time
Analysis Timeline
"Acquired Turns Pharmaceuticals for $6.7 billion, boosting M&A fantasy in the biotech sector."
"CEO Ken Frazier took a courageous stand against political actions, leading to a stampede of other firms joining, and was unanimously backed by his company."
"Saw a 14% decline due to disappointing earnings and outlooks."
"Stock plunged 8% after the company forecast a decline in profit for the current year."
"Identified as an 'early German market' opportunity, solid with future perspective for entry."
"Strong revenue growth and impressive sales from its key oncology drug, Keytruda, exceeded expectations."
"Sein Krebsmedikament Keytruder wurde in Kombination mit Modernas Impfstoff erwähnt, was positiv für die Studie ist."
"Negativ betroffen von Trumps Ankündigung, dass Amerikaner nicht mehr für Medikamente zahlen sollen als Europäer."